Table 1. Tuberculosis pipeline. Clinical-stage compounds for treating tuberculosis.

Source: BCIQ: BioCentury Online Intelligence; Working Group on New TB Drugs

Compound

Sponsors

Phase

Gatifloxacin

Institute of Research for Development

Phase III

Moxifloxacin

Bayer AG (Xetra:BAY)/Global Alliance for TB Drug Development (TB Alliance)

Phase III

PA-824

Novartis AG (NYSE:NVS; SIX:NOVN)/TB Alliance

Phase II

TMC207

Johnson & Johnson (NYSE:JNJ)/TB Alliance

Phase II

OPC-67683

Otsuka Pharmaceutical Co. Ltd. (Tokyo:4768)

Phase II

LL 3858

Lupin Ltd. (NSE:LUPIN; BSE:500257)

Phase II

Linezolid

Pfizer Inc. (NYSE:PFE)

Phase II

Rifapentine

sanofi-aventis Group (Euronext:SAN; NYSE:SNY)

Phase II

AZD5847

AstraZeneca plc (LSE:AZN; NYSE:AZN)

Phase I

SQ109

Sequella Inc.

Phase I

PF-2341272

Pfizer

Phase I